Is RAD 140 liver toxic? It can be. RAD 140, an investigational selective androgen receptor modulator, has injured liver tissue in some of those exposed, though not in all. The signal comes from a supervised trial, not from uncontrolled observation: raised liver enzymes were the most frequent adverse event in its only human trial, in women with advanced breast cancer.
The trial is not the whole story. Case reports, published accounts of single patients, describe men who turned yellow with jaundice from impaired bile flow; most recovered within months after exposure ended, and one needed intensive care. Outside the published trials, liver enzyme values are described as anything from sharply raised to normal, a spread that fits an injury striking only some of the exposed.
What is the compound? RAD140 is an orally active selective androgen receptor modulator (SARM), a class named by analogy with the selective oestrogen receptor modulators. Compounds of this class bind the androgen receptor, a protein inside cells that mediates the actions of androgens, and that binding is the core of the RAD 140 mechanism of action. Its first human test was a phase 1 trial in postmenopausal women with oestrogen receptor-positive, HER2-negative metastatic breast cancer, and its development history lies beyond the liver question.
This article weighs the trial data and the published cases of cholestasis (impaired bile flow from liver cells) against what is described outside the trials about liver support, alcohol and raised enzyme values. Testosterone suppression, cardiac effects and the other organ systems belong to the wider record of RAD 140 side effects.
What the human trial recorded about the liver
The liver was the loudest signal of the first-in-human phase 1 RAD 140 study. Among its 22 women with breast cancer the event recorded most often was a raised aspartate aminotransferase (AST), with raised alanine aminotransferase (ALT) and raised total bilirubin, the yellow pigment that liver cells clear from the blood, behind it at the rates the chart below gives; both enzymes leak into the blood from injured liver cells.
[Figure 1. Adverse events in RAD140’s phase 1 trial. In the only human trial, 22 women with advanced breast cancer took 50, 100 or 150 mg daily; raised AST and ALT were the commonest adverse events. Rates are pooled across doses, and the trial had no comparison group.]
Severity followed the same markers. Their rises reached grade 3 or 4, the top tiers of the adverse event grade scale that ranks each finding by its clinical severity, in 22.7% of participants.
Treatment-related adverse events were recorded in 17 of the 22 women, seven of them at grade 3 and none at grade 4. The record pools the dose levels. Dose escalation ran at 50, 100 or 150 mg administered once daily, 100 mg a day became the maximum tolerated dose, the highest given without unacceptable toxicity, and a RAD 140 half life of 44.7 hours supported the once-daily schedule; but the rates of raised liver values are given for all 22 women together. The authors of a later case report pointed to that pooled signal of raised AST, ALT and total bilirubin among the participants, and three limits qualify it: heavily pretreated cancer patients, small numbers, and no comparison group.
How bad is RAD-140 for the liver, and how often does injury happen?
Beyond the trial data, RAD-140 Reddit accounts describe the compound as anything from markedly hepatotoxic to harmless to liver tissue, and both positions recur together: the SARM RAD140 as more hepatotoxic than some orally active anabolic-androgenic steroids at one end, material of confirmed identity as posing no danger to liver tissue at the other, with serum cholesterol named instead as the variable affected.
Among the effects described outside the trials, liver enzyme findings vary just as widely. Values well above the reference range appear within the first weeks of exposure, even at low daily amounts, while other accounts give normal values and a few give falling ones; several note that the content of the material was never verified against its label, which makes any single result hard to attribute to RAD140. One account written from a clinical standpoint describes a young patient admitted to hospital with liver failure after exposure to a multi-compound supplement containing RAD140, and the published case literature is cited as the main reason for concern.
Similar cases of liver injury associated with RAD-140 have been reported, highlighting the potential hepatotoxicity of this SARM.
What the RAD-140 liver injury case reports describe
Every published case report drawn on here concerns one man in whom exposure to RAD140 was followed by drug-induced liver injury, and in most of them the injury showed as jaundice and itching. The earliest RAD-140 liver injury case report dates from 2020 and concerns the oldest of these men, whose age the table below gives; he had been exposed to two supplements, one containing RAD-140 and the other RAD-140 with LGD-4033 (ligandrol), another member of the same compound class.
Younger men fill the later reports. The man of the 2022 report presented, after the length of exposure the table gives, with diffuse abdominal pain, itching, jaundice and scleral icterus, a yellowing of the whites of the eyes; the man of the first 2023 report presented with nausea, vomiting, severe right upper quadrant abdominal pain and jaundice.
Two further men had been exposed for longer, for the lengths the table records: in the man of the second 2023 report the exposure preceded jaundice, nausea, fatigue, itching, dark urine and light stools, and a further man developed jaundice after his. The last two cases add severity and a second compound. The Australian report describes severe drug-induced liver injury in a young man, and the 2026 report describes a young man exposed to a supplement containing RAD-140 and andarine (S-4), another compound of the class.
With one patient to a report, attribution to RAD140 rests on excluding other causes: viral hepatitis and autoimmune panels were unremarkable in the man of the second 2023 report, and an extensive inpatient workup found no other definite cause in the man of the first.
Published RAD140 liver injury cases
Case
Product reported
Exposure before symptoms
How the injury showed
Outcome
2020, man aged 52
Two supplements, one with RAD-140, one with RAD-140 and LGD-4033; contents taken from labels
Not given in the source
Drug-induced liver injury with cholestasis on biopsy
Liver enzymes normal about 3 months after both supplements stopped
Nausea, vomiting, severe right upper abdominal pain, jaundice
Supportive care; liver panel normal at 2-month follow-up
2023, man aged 22
RAD-140
16 weeks
Jaundice, nausea, fatigue, itching, dark urine, light stools
Supportive care; enzymes normal 3 to 12 months after stopping
2024, man aged 29
RAD-140
3 months
Jaundice and raised liver enzymes
Symptoms resolved after stopping
2024, young man, Australia
RAD-140
Not given in the source
Severe liver injury
Not given in the source
2025, one patient
RAD-140
Not given in the source
Prolonged cholestasis
Resolved after corticosteroids
2026, young man
Supplement with RAD-140 and andarine (S-4)
Not given in the source
Severe cholestatic injury; bilirubin kept rising after stopping
Plasmapheresis; pancreatitis and acute kidney injury; intensive care
What blood tests, scans and biopsies showed
The blood tests in these reports share a cholestatic pattern, a profile led by the markers of impaired bile flow rather than by the enzymes released from injured liver cells. In the 2022 case total bilirubin reached the peak the table below gives. The 2023 liver panel, in other units, had the same shape, with ALT and AST far lower than alkaline phosphatase (ALP), the enzyme whose blood level rises when bile flow is impaired; for that patient the table also gives direct and total bilirubin and the international normalised ratio (INR), a standardised measure of how long blood takes to clot.
Imaging in the same patient found bile sludge on ultrasound and segmental narrowing of the intrahepatic ducts on magnetic resonance cholangiopancreatography (MRCP), a magnetic resonance scan that maps the bile and pancreatic ducts, while in the 2024 case ultrasound showed a hyperechoic lesion together with hepatic steatosis, an accumulation of fat within liver cells. Liver biopsy supplied the histological picture in three of the reports.
Cholestatic pattern; peak total bilirubin 38.5 mg/dL
Not given in the source
Intracytoplasmic and canalicular cholestasis, minimal portal inflammation
2023, man aged 22
ALP 5.3 µkat/L, ALT 1.66 µkat/L, AST 1.18 µkat/L, direct bilirubin 294 µmol/L, total bilirubin 427.5 µmol/L, INR 0.9
Bile sludge on ultrasound; segmental narrowing of intrahepatic ducts on MRCP; ERCP unremarkable
Mixed portal hepatitis, cholestasis, biliary reactive changes with ceroid-loaded macrophages
2024, man aged 29
Raised liver enzymes
Hepatic steatosis and a hyperechoic lesion on ultrasound
Not given in the source
Under the microscope the three biopsies told one story in three dialects. The 2022 biopsy showed intracytoplasmic cholestasis and minimal portal inflammation together with canalicular cholestasis, the retention of bile in the fine channels between adjacent liver cells; the 2023 biopsy showed mixed portal hepatitis, cholestasis and biliary reactive changes with ceroid-loaded macrophages; and the liver tissue from the earliest case, reported in 2020, showed diffuse centrilobular canalicular cholestasis, a prominent ductular reaction and a rare non-necrotising epithelioid granuloma.
How severe the worst cases became
The most severe RAD140-linked drug-induced liver injury reported to date is a 2026 case. In that patient bilirubin kept rising despite withdrawal of the compound and treatment with corticosteroids, so he needed plasmapheresis (the exchange of plasma to remove circulating substances); intensive care followed when pancreatitis and acute kidney injury complicated the course. Severity of that order is the exception among the published cases, and it marks the ceiling of what the record describes so far.
Two further cases sit below that ceiling: the Australian case, characterised as severe drug-induced liver injury, and a case of prolonged cholestasis that resolved only after corticosteroids. Because the cause can go unrecognised while exposure continues, the 2023 authors warn that drug-induced liver injury of this kind can likely progress to fulminant liver failure or to decompensated liver cirrhosis.
What kind of liver injury RAD140 is linked to
LiverTox, the National Institutes of Health database on drug-induced liver injury, links selective androgen receptor modulators as a class to cholestatic liver injury, in which bile no longer flows properly out of liver cells. The pattern resembles the injury seen with anabolic androgens, the testosterone-derived steroids with anabolic and androgenic activity, so the published reasoning on SARMs and the liver starts from a class resemblance rather than from a pathway specific to RAD140.
How the injury behaves is better described than how it arises. The 2023 authors call it idiosyncratic drug-induced liver injury, an unpredictable injury that strikes only some of those exposed to a given amount rather than all of them, and the 2020 report proposes a mechanism for two selective androgen receptor modulators, RAD-140 and LGD-4033, and so for the injury that links LGD 4033 and the liver. The histology carries most of the weight: the canalicular cholestasis in the biopsies matches the cholestatic pattern of the LiverTox monograph on the class.
Does liver support help on a RAD-140 cycle, and is there evidence for it?
Outside the published trials, liver support supplements, products marketed to protect liver tissue during drug exposure, are described in ways that show a convention rather than an observed benefit. No question comes up more often in connection with RAD140 and the liver, and it takes several forms: whether such a supplement is needed at all, which one, and when during exposure it should begin. The practice described varies widely.
In those accounts the supplements are commonly added from the first day of exposure, yet enzyme values rise above the reference range despite them, while liver function panels stay within the reference range where nothing was added; a smaller set of accounts asks instead whether the supplements reduce the compound’s effect.
Does TUDCA protect the liver on RAD-140?
TUDCA (tauroursodeoxycholic acid, a bile-acid derivative) is the liver support agent named most often alongside RAD-140 in accounts outside the published studies. Its timing is described in two ways, deferred until exposure has ended or begun early once liver enzyme values are found raised, so the timing follows the enzyme results rather than a settled rule.
Outside the trial record, TUDCA is described in some accounts as reducing the effect of RAD-140, which some give as a reason to omit it, and the amount and frequency of its administration are described in widely differing terms, with no amount or schedule agreed.
Does milk thistle protect the liver on RAD-140?
Milk thistle (silymarin) is described, outside the published trials, as a mild, familiar agent and is often named together with TUDCA; whether it is needed at all is sometimes left an open question.
In descriptions beyond the trials a narrower concern appears in a few accounts: that milk thistle competes with RAD-140 at the androgen receptor, so that administration in the morning might weaken the compound’s effects. A change in liver function test values attributable to milk thistle itself is seldom described.
Does NAC protect the liver on RAD-140, and when is it taken?
NAC (N-acetylcysteine, an amino-acid derivative) is described in accounts outside the published studies as an addition to low daily amounts of RAD140, and sometimes as preferred over milk thistle; at least one account describes daily NAC administration that did nothing to hold liver enzyme values down.
In those accounts timing does not converge. Some place NAC administration in the morning, before or at the same time as the compound, others elsewhere in the day, so no agreed schedule emerges, and NAC too is suspected of reducing the effect of the compound.
Is on-cycle liver support needed with RAD-140?
Beyond the trial data the need for liver support during exposure is contested, with three positions recurring. The first holds that liver support should accompany every exposure to RAD140, or to LGD-4033, because either compound is held to be hepatotoxic; the second holds that correctly identified material should not be hepatotoxic at all, so that cholesterol is the variable worth monitoring.
In those accounts the third position is empirical: measured blood values decide whether any supplement is added during exposure.
Does drinking alcohol on RAD-140 add to the liver risk?
Outside the published trials, alcohol during exposure to RAD-140 is described as something to avoid, on the recurring reasoning that liver tissue is already metabolising the compound. Occasional, light alcohol exposure is less settled, and heavy alcohol exposure on one occasion each week is a specific concern in at least one account.
Beyond the trial data, RAD-140 is also described as not taxing liver tissue unless alcohol or another hepatotoxic agent is added; that conditional position makes the combination, rather than the compound, the stated concern. Other substances are named in the same way, some as additional hepatic load and others as possible interactions with other medicines, raised alongside interactions with non-medicinal substances and usually left unresolved:
ibuprofen (additional hepatic load)
other orally administered compounds (additional hepatic load)
antidepressants (possible interaction)
acid-suppressing drugs (possible interaction)
prednisone (possible interaction)
Dose and length of exposure in the trial and the case reports
The trial administered 50, 100 or 150 mg once daily and reported its rates of raised liver enzymes for the 22 women together, not by dose level, so it cannot show whether larger amounts produced larger rises. Any comparison of RAD140 doses and cycle length across the literature has to read the amounts beside the length of exposure, because dose and duration together define exposure.
The case reports record widely varying lengths of exposure: drug-induced liver injury followed five weeks of exposure in the 24-year-old, three months in the 29-year-old and 16 weeks in the 22-year-old. No dose-response relationship can be read across them, because their daily amounts came from commercial supplements rather than from a controlled dosing schedule, and that absence fits the 2023 authors’ characterisation of the injury as idiosyncratic drug-induced liver injury, a form not tied to any fixed dose.
Novel selective androgen receptor modulators such as RAD140 may be associated with idiosyncratic drug-induced liver injury.
Does a higher dose or longer cycle of RAD-140 raise liver enzymes more?
Accounts outside the published studies describe higher daily amounts held over longer exposure as going together with liver enzyme values far above the reference range, but the pattern is not consistent: high values at low daily amounts within the first month of exposure are described too, and one account notes that sharply raised enzymes do not accompany every exposure at a lower amount.
Outside the trial record, the compound’s adverse effects are called dose-dependent in some accounts. The amounts and values behind these descriptions cannot be read as measurements, so what they establish is a direction, not a quantified relationship.
Reading raised liver values: enzymes, bilirubin and grades
In the phase 1 trial a grade 3 or 4 rise in AST or ALT marked a severe change on the adverse event scale, and such rises were the trial’s main severe liver finding. Both enzymes are held within liver cells and pass into the blood when those cells are injured, and so liver function tests report the liver enzymes AST and ALT beside ALP and INR; those values make up the liver side of RAD 140 blood work.
The case reports give the same panel a different shape. Their authors called the pattern cholestatic, with bilirubin and alkaline phosphatase rising most while ALT and AST rose comparatively less, and the biopsies matched that reading. A cholestatic pattern points to obstructed bile flow; a rise led by AST and ALT points to hepatocellular injury (injury to the liver cells themselves). The pattern bears on timing too: cholestasis can take weeks to months to normalise once the agent is withdrawn, so a single raised panel says little about where in that course a patient stands.
[Figure 2. Liver enzymes over 35 days, one case. In the 22-year-old man’s case, ALT was highest on day 1 and fell within a week, while alkaline phosphatase climbed to about 420 by day 21 and stayed highest: the bile-flow pattern. One patient; the paper does not state units.]
What do high liver enzymes on RAD-140 mean, and when should you stop?
In descriptions beyond the trials, high liver enzyme values during exposure to RAD-140 are read not as a diagnosis but as the commonest stated prompt for stopping, with retesting some weeks after exposure has ended; values already above the reference range on a baseline panel are described as grounds for not beginning exposure at all.
In those accounts several questions recur without settled answers: how long ALT and AST may take to settle after exposure ends before the interval counts as too long, and, in at least one account, how likely a second drug-induced liver injury is after an earlier one.
When should AST and ALT be checked on RAD-140?
AST and ALT are generally held to be checked first at baseline, before any hepatotoxic exposure begins, because a value can only be read as raised against a known starting point; repeat measurement is commonly described as periodic during exposure and again after it ends, with any abnormal value confirmed on a second test rather than acted on as a single result. The intervals between measurements are widely understood to depend on the agent and on clinical judgement.
Is it possible my liver is having problems?
Problems in liver tissue are possible. Among the effects described outside the trials, drug-induced liver injury is generally held to show as yellowing of the skin or of the whites of the eyes, itching, dark urine, pale stools or abdominal discomfort, and such signs are held to call for a liver function test and clinical assessment, because drug-induced liver injury can progress before it produces any symptoms. Liver enzyme values are also described as rising with no symptoms at all, so the absence of signs does not show that liver tissue is unaffected.
What happens to the liver after RAD140 is stopped
The 22-year-old shows the pace of recovery. His total bilirubin had fallen from a peak of 530 µmol/L to 188 µmol/L by the one-month follow-up, yet his liver enzymes took three to twelve months after the product was discontinued to normalise: cholestatic liver injury improves quickly and resolves slowly.
Liver enzymes normalized three to 12 months after product discontinuation.
He was not alone. The 52-year-old was the only one of these men with two supplements in his history, and he needed about three months after both were withdrawn before his enzymes were back to normal; the others were quicker: the 26-year-old’s liver function panel was normal at two-month follow-up with no recurrence of symptoms, the man of the 2022 case recovered from his drug-induced liver injury once exposure ended, and in the 29-year-old symptoms resolved once the compound was discontinued.
What sets the interval is the pattern of injury rather than the compound. Cholestasis can take weeks to months to normalise with supportive care alone, one atypical case of prolonged cholestasis resolved only after corticosteroids were given, and the case reports read together make recovery the rule once exposure to RAD140 stops.
The exception is the 2026 case, in which bilirubin went on rising after the compound was stopped. Taken together, these outcomes make withdrawal the main determinant of recovery without guaranteeing it, and the long-term effects and risks of exposure to such compounds remain unclear.
What the products in the reports contained
In several case reports the material held more than RAD140. In the 2020 case the contents were known only from the labels, and the patient had been exposed to two supplements, one of them also containing LGD-4033; the supplement in the 2026 case contained andarine alongside RAD-140, so there too the injury followed exposure to more than one compound.
Under-dosing weakens any reading of these cases by their labels. Australia’s Therapeutic Goods Administration (TGA) tested unapproved SARM products and found them significantly under-dosed, so a label is no proof of content, and whether a product is legit RAD 140 bears directly on the case literature: where the amount behind an injury cannot be fixed, neither a threshold nor a dose-response relationship can be drawn from the case series, and a second compound can shape the clinical course without appearing in the history.
For research material, documentation has to stand in for the label claim. Each lot of the RAD-140 for sale supplied here for laboratory research carries batch and purity data, and the other compounds named in these case reports, where stocked for research, sit with our other UK SARMs.
Where RAD140 stands with regulators
The United States Food and Drug Administration (FDA) has not approved RAD140 as a medicine. It remains an investigational agent, one that entered development under the name vosilasarm and has been studied in oestrogen receptor-positive, HER2-negative metastatic breast cancer.
Two regulatory steps beyond that approval status appear in this article’s sources. In the United States, the authors of the 2023 case of the 22-year-old ask physicians to report suspected drug-induced liver injury to the FDA through MedWatch, the agency’s voluntary adverse event reporting programme; in Australia, the TGA tested unapproved SARM products itself and followed the testing with a safety alert.
Gaps in the liver evidence on RAD140
The human evidence on whether testolone is liver toxic rests on one small phase 1 trial in heavily pretreated cancer patients, with 22 participants, three dose levels and no comparison group, and beyond it on a series of case reports, each describing a single patient. Two of those reports involved products holding more than one compound, and in the earlier of them the contents were taken from the labels rather than measured, which weakens any attribution to RAD140 alone.
The authors of these reports judge causation by the timing of exposure and the exclusion of other causes, not by rechallenge or a biomarker, so attribution remains a clinical judgement rather than a measurement. No rate of injury can be calculated from such a series, because the number of exposures outside trials is unknown, and the long-term effects and risks of such compounds are not established.
Three further effects rest on descriptions outside the trials alone, because no published study among this article’s sources has measured them: the effects of the liver support supplements TUDCA, milk thistle and NAC; the effect of alcohol alongside the compound; and the dose-linked enzyme rises.
[Figure 3. How doctors attributed one liver injury. In the 22-year-old man’s case, RAD140 was named as the cause because jaundice followed 16 weeks of exposure and tests excluded viral, autoimmune, inherited and bile-duct causes; no test measured RAD140 itself, so the diagnosis is a clinical judgement.]
Important information. This article summarises published research and case reports, and notes where effects are described outside the published trials. It is not medical advice, and Max Muscle Labs does not give dosing guidance or any information implying human use. Many of the compounds discussed here are not approved for human use by the MHRA, the FDA or any other regulator, and many are prohibited in sport by WADA. Products sold by Max Muscle Labs are supplied strictly for laboratory and analytical research use and are not for human or veterinary consumption.
Check what you remember
4 questions on this article; the right answer is marked.
In the only human trial of RAD140, which finding was the most frequent treatment-emergent adverse event?
Raised AST, a liver enzyme ✓
Raised total bilirubin
Low blood phosphate level
Vomiting and loss of appetite
Raised AST was recorded in 59.1% of the 22 women, ahead of ALT at 45.5% and bilirubin, vomiting and appetite loss at 27.3% each.
What pattern of liver injury do the published RAD140 case reports mostly describe?
Hepatocellular, led by AST and ALT
Cholestatic, led by impaired bile flow ✓
Fatty liver, led by fat in liver cells
Autoimmune, led by antibody markers
Bilirubin and alkaline phosphatase rose far more than ALT and AST, and the autoimmune and viral panels were unremarkable.
How did the 2023 case report authors characterise the liver injury linked to RAD140?
Predictable, rising in step with the amount used
Cumulative, building up steadily over long exposure
Idiosyncratic, affecting only some of those exposed ✓
Contaminant-led, caused by impurities in the products
The authors call it idiosyncratic drug-induced liver injury, an unpredictable injury that strikes only some people and is not tied to a fixed amount.
What happened in most of the published cases once exposure to RAD140 ended?
Liver values normalised within a few days
Injury progressed on to liver cirrhosis
Liver values recovered only with corticosteroids
Liver values normalised over weeks to months ✓
Cholestatic injury resolves slowly: in the 22-year-old, liver enzymes took three to 12 months to normalise after the product was stopped.
Specialty Registrar in Chemical Pathology and Metabolic Medicine
Matthew Waite is a specialty registrar in chemical pathology and metabolic medicine at Imperial College Healthcare NHS Trust. Matthew specialises in cardiology and lipidology.
Is RAD-140 bad for kidneys: no direct kidney harm has been shown, but one case report records acute kidney injury during severe drug-induced liver injury.
RAD 140 lethargy, like aggression, anxiety and insomnia, is unproven: the only human trial, in 22 women, listed none among its frequent adverse events.
Is RAD140 liver toxic? What trials and case reports show
By Ailsa Gemmell · Reviewed by Matthew Waite, MB BChir
Published · Updated · 22 min read
Is RAD 140 liver toxic?
Is RAD 140 liver toxic? It can be. RAD 140, an investigational selective androgen receptor modulator, has injured liver tissue in some of those exposed, though not in all. The signal comes from a supervised trial, not from uncontrolled observation: raised liver enzymes were the most frequent adverse event in its only human trial, in women with advanced breast cancer.
The trial is not the whole story. Case reports, published accounts of single patients, describe men who turned yellow with jaundice from impaired bile flow; most recovered within months after exposure ended, and one needed intensive care. Outside the published trials, liver enzyme values are described as anything from sharply raised to normal, a spread that fits an injury striking only some of the exposed.
What is the compound? RAD140 is an orally active selective androgen receptor modulator (SARM), a class named by analogy with the selective oestrogen receptor modulators. Compounds of this class bind the androgen receptor, a protein inside cells that mediates the actions of androgens, and that binding is the core of the RAD 140 mechanism of action. Its first human test was a phase 1 trial in postmenopausal women with oestrogen receptor-positive, HER2-negative metastatic breast cancer, and its development history lies beyond the liver question.
This article weighs the trial data and the published cases of cholestasis (impaired bile flow from liver cells) against what is described outside the trials about liver support, alcohol and raised enzyme values. Testosterone suppression, cardiac effects and the other organ systems belong to the wider record of RAD 140 side effects.
What the human trial recorded about the liver
The liver was the loudest signal of the first-in-human phase 1 RAD 140 study. Among its 22 women with breast cancer the event recorded most often was a raised aspartate aminotransferase (AST), with raised alanine aminotransferase (ALT) and raised total bilirubin, the yellow pigment that liver cells clear from the blood, behind it at the rates the chart below gives; both enzymes leak into the blood from injured liver cells.
Severity followed the same markers. Their rises reached grade 3 or 4, the top tiers of the adverse event grade scale that ranks each finding by its clinical severity, in 22.7% of participants.
Treatment-related adverse events were recorded in 17 of the 22 women, seven of them at grade 3 and none at grade 4. The record pools the dose levels. Dose escalation ran at 50, 100 or 150 mg administered once daily, 100 mg a day became the maximum tolerated dose, the highest given without unacceptable toxicity, and a RAD 140 half life of 44.7 hours supported the once-daily schedule; but the rates of raised liver values are given for all 22 women together. The authors of a later case report pointed to that pooled signal of raised AST, ALT and total bilirubin among the participants, and three limits qualify it: heavily pretreated cancer patients, small numbers, and no comparison group.
How bad is RAD-140 for the liver, and how often does injury happen?
Beyond the trial data, RAD-140 Reddit accounts describe the compound as anything from markedly hepatotoxic to harmless to liver tissue, and both positions recur together: the SARM RAD140 as more hepatotoxic than some orally active anabolic-androgenic steroids at one end, material of confirmed identity as posing no danger to liver tissue at the other, with serum cholesterol named instead as the variable affected.
Among the effects described outside the trials, liver enzyme findings vary just as widely. Values well above the reference range appear within the first weeks of exposure, even at low daily amounts, while other accounts give normal values and a few give falling ones; several note that the content of the material was never verified against its label, which makes any single result hard to attribute to RAD140. One account written from a clinical standpoint describes a young patient admitted to hospital with liver failure after exposure to a multi-compound supplement containing RAD140, and the published case literature is cited as the main reason for concern.
What the RAD-140 liver injury case reports describe
Every published case report drawn on here concerns one man in whom exposure to RAD140 was followed by drug-induced liver injury, and in most of them the injury showed as jaundice and itching. The earliest RAD-140 liver injury case report dates from 2020 and concerns the oldest of these men, whose age the table below gives; he had been exposed to two supplements, one containing RAD-140 and the other RAD-140 with LGD-4033 (ligandrol), another member of the same compound class.
Younger men fill the later reports. The man of the 2022 report presented, after the length of exposure the table gives, with diffuse abdominal pain, itching, jaundice and scleral icterus, a yellowing of the whites of the eyes; the man of the first 2023 report presented with nausea, vomiting, severe right upper quadrant abdominal pain and jaundice.
Two further men had been exposed for longer, for the lengths the table records: in the man of the second 2023 report the exposure preceded jaundice, nausea, fatigue, itching, dark urine and light stools, and a further man developed jaundice after his. The last two cases add severity and a second compound. The Australian report describes severe drug-induced liver injury in a young man, and the 2026 report describes a young man exposed to a supplement containing RAD-140 and andarine (S-4), another compound of the class.
With one patient to a report, attribution to RAD140 rests on excluding other causes: viral hepatitis and autoimmune panels were unremarkable in the man of the second 2023 report, and an extensive inpatient workup found no other definite cause in the man of the first.
Published RAD140 liver injury cases
What blood tests, scans and biopsies showed
The blood tests in these reports share a cholestatic pattern, a profile led by the markers of impaired bile flow rather than by the enzymes released from injured liver cells. In the 2022 case total bilirubin reached the peak the table below gives. The 2023 liver panel, in other units, had the same shape, with ALT and AST far lower than alkaline phosphatase (ALP), the enzyme whose blood level rises when bile flow is impaired; for that patient the table also gives direct and total bilirubin and the international normalised ratio (INR), a standardised measure of how long blood takes to clot.
Imaging in the same patient found bile sludge on ultrasound and segmental narrowing of the intrahepatic ducts on magnetic resonance cholangiopancreatography (MRCP), a magnetic resonance scan that maps the bile and pancreatic ducts, while in the 2024 case ultrasound showed a hyperechoic lesion together with hepatic steatosis, an accumulation of fat within liver cells. Liver biopsy supplied the histological picture in three of the reports.
Blood tests, scans and biopsies by case
Under the microscope the three biopsies told one story in three dialects. The 2022 biopsy showed intracytoplasmic cholestasis and minimal portal inflammation together with canalicular cholestasis, the retention of bile in the fine channels between adjacent liver cells; the 2023 biopsy showed mixed portal hepatitis, cholestasis and biliary reactive changes with ceroid-loaded macrophages; and the liver tissue from the earliest case, reported in 2020, showed diffuse centrilobular canalicular cholestasis, a prominent ductular reaction and a rare non-necrotising epithelioid granuloma.
How severe the worst cases became
The most severe RAD140-linked drug-induced liver injury reported to date is a 2026 case. In that patient bilirubin kept rising despite withdrawal of the compound and treatment with corticosteroids, so he needed plasmapheresis (the exchange of plasma to remove circulating substances); intensive care followed when pancreatitis and acute kidney injury complicated the course. Severity of that order is the exception among the published cases, and it marks the ceiling of what the record describes so far.
Two further cases sit below that ceiling: the Australian case, characterised as severe drug-induced liver injury, and a case of prolonged cholestasis that resolved only after corticosteroids. Because the cause can go unrecognised while exposure continues, the 2023 authors warn that drug-induced liver injury of this kind can likely progress to fulminant liver failure or to decompensated liver cirrhosis.
What kind of liver injury RAD140 is linked to
LiverTox, the National Institutes of Health database on drug-induced liver injury, links selective androgen receptor modulators as a class to cholestatic liver injury, in which bile no longer flows properly out of liver cells. The pattern resembles the injury seen with anabolic androgens, the testosterone-derived steroids with anabolic and androgenic activity, so the published reasoning on SARMs and the liver starts from a class resemblance rather than from a pathway specific to RAD140.
How the injury behaves is better described than how it arises. The 2023 authors call it idiosyncratic drug-induced liver injury, an unpredictable injury that strikes only some of those exposed to a given amount rather than all of them, and the 2020 report proposes a mechanism for two selective androgen receptor modulators, RAD-140 and LGD-4033, and so for the injury that links LGD 4033 and the liver. The histology carries most of the weight: the canalicular cholestasis in the biopsies matches the cholestatic pattern of the LiverTox monograph on the class.
Does liver support help on a RAD-140 cycle, and is there evidence for it?
Outside the published trials, liver support supplements, products marketed to protect liver tissue during drug exposure, are described in ways that show a convention rather than an observed benefit. No question comes up more often in connection with RAD140 and the liver, and it takes several forms: whether such a supplement is needed at all, which one, and when during exposure it should begin. The practice described varies widely.
In those accounts the supplements are commonly added from the first day of exposure, yet enzyme values rise above the reference range despite them, while liver function panels stay within the reference range where nothing was added; a smaller set of accounts asks instead whether the supplements reduce the compound’s effect.
Does TUDCA protect the liver on RAD-140?
TUDCA (tauroursodeoxycholic acid, a bile-acid derivative) is the liver support agent named most often alongside RAD-140 in accounts outside the published studies. Its timing is described in two ways, deferred until exposure has ended or begun early once liver enzyme values are found raised, so the timing follows the enzyme results rather than a settled rule.
Outside the trial record, TUDCA is described in some accounts as reducing the effect of RAD-140, which some give as a reason to omit it, and the amount and frequency of its administration are described in widely differing terms, with no amount or schedule agreed.
Does milk thistle protect the liver on RAD-140?
Milk thistle (silymarin) is described, outside the published trials, as a mild, familiar agent and is often named together with TUDCA; whether it is needed at all is sometimes left an open question.
In descriptions beyond the trials a narrower concern appears in a few accounts: that milk thistle competes with RAD-140 at the androgen receptor, so that administration in the morning might weaken the compound’s effects. A change in liver function test values attributable to milk thistle itself is seldom described.
Does NAC protect the liver on RAD-140, and when is it taken?
NAC (N-acetylcysteine, an amino-acid derivative) is described in accounts outside the published studies as an addition to low daily amounts of RAD140, and sometimes as preferred over milk thistle; at least one account describes daily NAC administration that did nothing to hold liver enzyme values down.
In those accounts timing does not converge. Some place NAC administration in the morning, before or at the same time as the compound, others elsewhere in the day, so no agreed schedule emerges, and NAC too is suspected of reducing the effect of the compound.
Is on-cycle liver support needed with RAD-140?
Beyond the trial data the need for liver support during exposure is contested, with three positions recurring. The first holds that liver support should accompany every exposure to RAD140, or to LGD-4033, because either compound is held to be hepatotoxic; the second holds that correctly identified material should not be hepatotoxic at all, so that cholesterol is the variable worth monitoring.
In those accounts the third position is empirical: measured blood values decide whether any supplement is added during exposure.
Does drinking alcohol on RAD-140 add to the liver risk?
Outside the published trials, alcohol during exposure to RAD-140 is described as something to avoid, on the recurring reasoning that liver tissue is already metabolising the compound. Occasional, light alcohol exposure is less settled, and heavy alcohol exposure on one occasion each week is a specific concern in at least one account.
Beyond the trial data, RAD-140 is also described as not taxing liver tissue unless alcohol or another hepatotoxic agent is added; that conditional position makes the combination, rather than the compound, the stated concern. Other substances are named in the same way, some as additional hepatic load and others as possible interactions with other medicines, raised alongside interactions with non-medicinal substances and usually left unresolved:
Dose and length of exposure in the trial and the case reports
The trial administered 50, 100 or 150 mg once daily and reported its rates of raised liver enzymes for the 22 women together, not by dose level, so it cannot show whether larger amounts produced larger rises. Any comparison of RAD140 doses and cycle length across the literature has to read the amounts beside the length of exposure, because dose and duration together define exposure.
The case reports record widely varying lengths of exposure: drug-induced liver injury followed five weeks of exposure in the 24-year-old, three months in the 29-year-old and 16 weeks in the 22-year-old. No dose-response relationship can be read across them, because their daily amounts came from commercial supplements rather than from a controlled dosing schedule, and that absence fits the 2023 authors’ characterisation of the injury as idiosyncratic drug-induced liver injury, a form not tied to any fixed dose.
Does a higher dose or longer cycle of RAD-140 raise liver enzymes more?
Accounts outside the published studies describe higher daily amounts held over longer exposure as going together with liver enzyme values far above the reference range, but the pattern is not consistent: high values at low daily amounts within the first month of exposure are described too, and one account notes that sharply raised enzymes do not accompany every exposure at a lower amount.
Outside the trial record, the compound’s adverse effects are called dose-dependent in some accounts. The amounts and values behind these descriptions cannot be read as measurements, so what they establish is a direction, not a quantified relationship.
Reading raised liver values: enzymes, bilirubin and grades
In the phase 1 trial a grade 3 or 4 rise in AST or ALT marked a severe change on the adverse event scale, and such rises were the trial’s main severe liver finding. Both enzymes are held within liver cells and pass into the blood when those cells are injured, and so liver function tests report the liver enzymes AST and ALT beside ALP and INR; those values make up the liver side of RAD 140 blood work.
The case reports give the same panel a different shape. Their authors called the pattern cholestatic, with bilirubin and alkaline phosphatase rising most while ALT and AST rose comparatively less, and the biopsies matched that reading. A cholestatic pattern points to obstructed bile flow; a rise led by AST and ALT points to hepatocellular injury (injury to the liver cells themselves). The pattern bears on timing too: cholestasis can take weeks to months to normalise once the agent is withdrawn, so a single raised panel says little about where in that course a patient stands.
What do high liver enzymes on RAD-140 mean, and when should you stop?
In descriptions beyond the trials, high liver enzyme values during exposure to RAD-140 are read not as a diagnosis but as the commonest stated prompt for stopping, with retesting some weeks after exposure has ended; values already above the reference range on a baseline panel are described as grounds for not beginning exposure at all.
In those accounts several questions recur without settled answers: how long ALT and AST may take to settle after exposure ends before the interval counts as too long, and, in at least one account, how likely a second drug-induced liver injury is after an earlier one.
When should AST and ALT be checked on RAD-140?
AST and ALT are generally held to be checked first at baseline, before any hepatotoxic exposure begins, because a value can only be read as raised against a known starting point; repeat measurement is commonly described as periodic during exposure and again after it ends, with any abnormal value confirmed on a second test rather than acted on as a single result. The intervals between measurements are widely understood to depend on the agent and on clinical judgement.
Is it possible my liver is having problems?
Problems in liver tissue are possible. Among the effects described outside the trials, drug-induced liver injury is generally held to show as yellowing of the skin or of the whites of the eyes, itching, dark urine, pale stools or abdominal discomfort, and such signs are held to call for a liver function test and clinical assessment, because drug-induced liver injury can progress before it produces any symptoms. Liver enzyme values are also described as rising with no symptoms at all, so the absence of signs does not show that liver tissue is unaffected.
What happens to the liver after RAD140 is stopped
The 22-year-old shows the pace of recovery. His total bilirubin had fallen from a peak of 530 µmol/L to 188 µmol/L by the one-month follow-up, yet his liver enzymes took three to twelve months after the product was discontinued to normalise: cholestatic liver injury improves quickly and resolves slowly.
He was not alone. The 52-year-old was the only one of these men with two supplements in his history, and he needed about three months after both were withdrawn before his enzymes were back to normal; the others were quicker: the 26-year-old’s liver function panel was normal at two-month follow-up with no recurrence of symptoms, the man of the 2022 case recovered from his drug-induced liver injury once exposure ended, and in the 29-year-old symptoms resolved once the compound was discontinued.
What sets the interval is the pattern of injury rather than the compound. Cholestasis can take weeks to months to normalise with supportive care alone, one atypical case of prolonged cholestasis resolved only after corticosteroids were given, and the case reports read together make recovery the rule once exposure to RAD140 stops.
The exception is the 2026 case, in which bilirubin went on rising after the compound was stopped. Taken together, these outcomes make withdrawal the main determinant of recovery without guaranteeing it, and the long-term effects and risks of exposure to such compounds remain unclear.
What the products in the reports contained
In several case reports the material held more than RAD140. In the 2020 case the contents were known only from the labels, and the patient had been exposed to two supplements, one of them also containing LGD-4033; the supplement in the 2026 case contained andarine alongside RAD-140, so there too the injury followed exposure to more than one compound.
Under-dosing weakens any reading of these cases by their labels. Australia’s Therapeutic Goods Administration (TGA) tested unapproved SARM products and found them significantly under-dosed, so a label is no proof of content, and whether a product is legit RAD 140 bears directly on the case literature: where the amount behind an injury cannot be fixed, neither a threshold nor a dose-response relationship can be drawn from the case series, and a second compound can shape the clinical course without appearing in the history.
For research material, documentation has to stand in for the label claim. Each lot of the RAD-140 for sale supplied here for laboratory research carries batch and purity data, and the other compounds named in these case reports, where stocked for research, sit with our other UK SARMs.
Where RAD140 stands with regulators
The United States Food and Drug Administration (FDA) has not approved RAD140 as a medicine. It remains an investigational agent, one that entered development under the name vosilasarm and has been studied in oestrogen receptor-positive, HER2-negative metastatic breast cancer.
Two regulatory steps beyond that approval status appear in this article’s sources. In the United States, the authors of the 2023 case of the 22-year-old ask physicians to report suspected drug-induced liver injury to the FDA through MedWatch, the agency’s voluntary adverse event reporting programme; in Australia, the TGA tested unapproved SARM products itself and followed the testing with a safety alert.
Gaps in the liver evidence on RAD140
The human evidence on whether testolone is liver toxic rests on one small phase 1 trial in heavily pretreated cancer patients, with 22 participants, three dose levels and no comparison group, and beyond it on a series of case reports, each describing a single patient. Two of those reports involved products holding more than one compound, and in the earlier of them the contents were taken from the labels rather than measured, which weakens any attribution to RAD140 alone.
The authors of these reports judge causation by the timing of exposure and the exclusion of other causes, not by rechallenge or a biomarker, so attribution remains a clinical judgement rather than a measurement. No rate of injury can be calculated from such a series, because the number of exposures outside trials is unknown, and the long-term effects and risks of such compounds are not established.
Three further effects rest on descriptions outside the trials alone, because no published study among this article’s sources has measured them: the effects of the liver support supplements TUDCA, milk thistle and NAC; the effect of alcohol alongside the compound; and the dose-linked enzyme rises.
Check what you remember
4 questions on this article; the right answer is marked.
Raised AST was recorded in 59.1% of the 22 women, ahead of ALT at 45.5% and bilirubin, vomiting and appetite loss at 27.3% each.
Bilirubin and alkaline phosphatase rose far more than ALT and AST, and the autoimmune and viral panels were unremarkable.
The authors call it idiosyncratic drug-induced liver injury, an unpredictable injury that strikes only some people and is not tied to a fixed amount.
Cholestatic injury resolves slowly: in the 22-year-old, liver enzymes took three to 12 months to normalise after the product was stopped.
Ailsa Gemmell · NHS Greater Glasgow and Clyde
Specialty Registrar in Gastroenterology
Ailsa Gemmell is a specialty registrar in gastroenterology at NHS Greater Glasgow and Clyde. Ailsa specialises in hepatology and liver safety.
Matthew Waite, MB BChir · Imperial College Healthcare · Last reviewed
Specialty Registrar in Chemical Pathology and Metabolic Medicine
Matthew Waite is a specialty registrar in chemical pathology and metabolic medicine at Imperial College Healthcare NHS Trust. Matthew specialises in cardiology and lipidology.
Related Posts
Does RAD 140 shrink balls? Hormone suppression and recovery
Does RAD 140 shrink balls: RAD140 can lower LH and FSH, and a case report recorded hormone levels that returned to normal once exposure ended.
Is RAD-140 bad for kidneys? What the case reports show
Is RAD-140 bad for kidneys: no direct kidney harm has been shown, but one case report records acute kidney injury during severe drug-induced liver injury.
RAD 140 lethargy: mood, sleep and what the evidence shows
RAD 140 lethargy, like aggression, anxiety and insomnia, is unproven: the only human trial, in 22 women, listed none among its frequent adverse events.
Is MK-677 liver toxic? The liver and kidney evidence
Is MK-677 liver toxic: trials found it well tolerated, but a case report links it alone to raised liver enzymes that settled once exposure ended.